BELL Belluscura Plc

TIDMBELL

Belluscura PLC

25 October 2021

Belluscura PLC

("Belluscura" or the "Company")

Product wins Top Award at US Trade show

X-PLO R(TM) wins gold award at Medtrade East 2021 in Atlanta

LONDON, U.K. AND PLANO, TX, U.S. (25 October 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology , announces that its X-PLO R(TM) portable oxygen concentrator won the Providers' Choice Gold, the highest accolade to be given at Medtrade East in Atlanta, the largest home medical equipment trade show and conference in the U.S.

The X-PLO R(TM) weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world's first modular portable oxygen concentrator and that it generates more oxygen by weight than any other US Food & Drug Administration ("FDA") cleared POC in its class.

The X-PLO(2) R (TM) can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. The X-PLO R (TM) is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices.

Robert Rauker, CEO of Belluscura plc, said : "It is fantastic news and a great achievement that our portable oxygen concentrator has received the highest accolade given by the largest home medical equipment trade show and conference in the U.S. This award solidifies the strong demand we are receiving for the product and we will update shareholders with expected unit deliveries for 2021 and 2022 in the near future."

For further information please contact:

 
 Belluscura plc                                                          www.belluscura.com 
 Robert Rauker, Chief Executive                                             via Walbrook PR 
  Officer 
 Anthony Dyer, Chief Financial 
  Officer 
 
 SPARK Advisory Partners Limited                                   Tel: +44 (0)20 3368 3550 
  (NOMAD) 
 Neil Baldwin 
 
 Dowgate Capital Limited (Broker)                                  Tel: +44 (0)20 3903 7715 
 James Serjeant / Nicholas Chambers 
 
 Walbrook PR Ltd (Media & Investor    Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com 
  Relations) 
 Paul McManus / Sam Allen                            Mob: +44 (0)7980 541 893 / +44 (0)7502 
                                                                                    558 258 
 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFESFFLEFSEES

(END) Dow Jones Newswires

October 25, 2021 02:00 ET (06:00 GMT)

Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024